Oppenheimer maintains Evolent Health at Outperform, raises price target to $7 from $6

Oppenheimer kept its Outperform rating on Evolent Health and raised its price target to $7 from $6, suggesting a 54.2% upside from the Nov 5 close of $4.54, according to the firm.

Original reporting
Published Nov 6, 2026, 5:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 5:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oppenheimer maintains Evolent Health at Outperform, raises price target to $7 from $6 — source image
Decision brief

The 30-second read

$EVHBullishLow
01

Why it matters

The upgrade may trigger short‑term buying pressure but lacks underlying earnings surprise.

02

Market read

A modest analyst upgrade for a small‑cap health‑tech stock; limited broader market impact.

03

What to watch

No new fundamental data; upgrade based on analyst opinion alone.

Relevance 4/10Novelty 3/10Timing: today

Background

Evolent Health is a provider of technology‑enabled health services; the rating change is the sole news item.

Company-level read

Ticker impact

$EVHBullishMedium confidence
Context

Oppenheimer raised its price target for Evolent Health to $7 from $6, indicating a potential upside.

Expected impact

potential pressure upward as investors price in the higher target

Evidence & confidence

Target raise implies ~54% upside from recent close, likely to attract buying interest.

Market effects

May lift sentiment in the health‑tech sector.

Limited to US small‑cap market.

Minimal.

Counterpoint

Target raise could be premature if earnings miss expectations.

Key entities

  • Evolent Health

    US‑listed health‑tech firm (ticker EVH).

  • Oppenheimer

    Equity research firm issuing the rating change.

Related articles

$EVHMedAI 8/10

EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook

EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.

$EVHMed

Evolent Health, Inc. Q3 2026 Earnings Call Summary

Evolent Health reported 11% sequential revenue growth driven by Highmark Performance Suite and contractual adjustments. MER improved to 93%. Management prioritizes margin expansion and cash generation, with oncology expected to represent over 70% of revenue by 2027. AI platform scales, processing 1M cases annually. Management reiterated 2027 Adjusted EBITDA confidence of $150M+ and plans $50M debt reduction by 2026 year-end.

$EVHMedAI 8/10

Evolent Health (EVH) Q3 2026 Earnings Call Transcript

Evolent Health (EVH) reiterated its full-year revenue guidance of $2.6B-$2.7B and raised Adjusted EBITDA guidance to $130M-$135M. The company reported customer contract renewals and expansions, including a 4-year renewal with its largest Surgical Management customer and expansions in oncology and specialty services.

$EVHMed

Evolent Health: Q3 Earnings Snapshot

Evolent Health (EVH) reported a Q3 loss of $23.6M, or 21 cents per share, with adjusted earnings of 6 cents per share, meeting expectations. Revenue was $725.4M, below the $734.3M forecast. The company expects full-year revenue between $2.6B and $2.7B.